Synthesis, Antiproliferative, and Molecular Docking Studies of 3-Mercapto-1,2,4-Triazole Derivatives as Combretastatin A-4 Analogs

被引：1

作者：

Balakit, Asim A. ^{[1
]}

Abu-El-Halawa, Rajab ^{[2
]}

Alsadoon, Ali H. ^{[1
]}

Ghaleb, Rana A. ^{[3
]}

Alfadhel, Sanad ^{[4
]}

Ayrim, Nabel B. ^{[5
]}

Alsultan, Elaf S. ^{[6
]}

机构：

[1] Univ Babylon, Coll Pharm, Babylon, Iraq

[2] Univ Al Al Bayt, Fac Sci, Dept Chem, Mafraq, Jordan

[3] Univ Babylon, Coll Med, Dept Human Anat, Babylon, Iraq

[4] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland

[5] Mustansiriyah Univ, Coll Sci, Dept Chem, Baghdad, Iraq

[6] Merjan Teaching Hosp, Minist Hlth, Babylon, Iraq

来源：

PHARMACEUTICAL CHEMISTRY JOURNAL | 2023年 / 57卷 / 07期

关键词：

mercapto; triazole; combretastatin; antiproliferative; antitubulin; ANTIOXIDANT; HYBRIDS; TUBULIN; SITE;

D O I：

10.1007/s11094-023-02977-z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In the present work, a series of 1,2,4-triazole derivatives are designed as combretastatin A-4 analogs with the 4-nitrophenyl group and different aliphatic alkyl substituents, the designed compounds were synthesized and characterized by FT-IR, 1H NMR,13C NMR spectroscopy, and mass spectrometry. The synthesized compounds were tested as antiproliferative agents against human cancer laryngeal (Hep-2) cell line, the cytotoxicity of the synthesized compounds was evaluated by the treatment of a human normal kidney (Vero) cell line. The obtained results revealed that compound 5c, which has a n-propyl substituent, is the most active one and has lowest cytotoxicity against normal cells. This compound has the lowest IC50 value within the tested series; consequently, compound 5c could be considered a promising antiproliferative agent and a good candidate for further pharmacological studies. Molecular docking studies were implemented to determine the affinity of the synthesized compound toward the colchicine binding site.

引用

页码：1001 / 1007

页数：7

共 30 条

[1] Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities [J].